You are about to leave jnjmedicaldevices.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
BIOPATCH® Protective Disk with CHG
BIOPATCH Protective Disk with CHG - the #1 selling CHG dressing on the market with a 1A CDC recommendation.1*
Features & Benefits
Protect All Lines. Protect All Lives.™
50 patients die each day in US hospitals due to bloodstream infections.2,3 Catheter-related bloodstream infections are preventable, often fatal and can significantly impact hospital CMS reimbursement. BIOPATCH Disk is the only dressing with CHG proven in multiple, randomized controlled trials to reduce the incidence of catheter-related bloodstream infections in central venous and arterial catheters.4,5
PIV-BSI: An Under-Evaluated Complication6
In a retrospective database analysis, 1.45% of patients had a PIV-BSI.7 Patients with PIV-associated complications have longer length of stay (LOS), higher costs, and are at greater risk of death than patients without.7
Prepping the Skin Is Not Enough8
BIOPATCH Disk provides 360º protection around the insertion site up to 7 days.8 Within hours of thorough antiseptic application, resident bacteria quickly re-colonize the skin surface.8 Patients need to be protected from their own skin’s microflora for ongoing antisepsis between dressing changes9 regardless of the type of vascular access device used.9
Improve the Patient Experience
Use BIOPATCH Disk as part of a PIV bundle to help protect the insertion site. Peripheral IVs are the most frequently used invasive device in hospitals,6 and standards of care now recommend clinically indicated replacement. This change can lead to improved outcomes, increased efficiency, and better patient experience. There is no risk-free line, and vigilance is required with any vascular device placement.10
Resources
Resources
Resources
BIOPATCH Disk PIV In Service Video
03:35
BIOPATCH Disk vs Tegaderm™ CHG Fluid Management
00:53
BIOPATCH Disk BSI Awareness Video
03:09
Supporting Documentation
Clinical Evidence
BIOPATCH Disk Clinical Compendium
PIV Clinical Compendium
DeVries PIV JAVA Publication
Product Support
BSI Quick Reference Page
PIV Skin Story
GuardIVa® Technical Report
BIOPATCH Disk, GuardIVa® and AEGIS™ In Vitro Comparison
Visualization Brochure
Biopatch vs. Aegis Fact Checker
BIOPATCH Core Brochure
BIOPATCH Disk Pocket Insertion Card
BIOPATCH Disk Value Proposition
BIOPATCH Disk Drain Fact Sheet
Review the Facts – Percutaneous Devices
BIOPATCH Point Prevalence Brochure
BIOPATCH Disk vs. Tegaderm CHG
BIOPATCH Kling-Z In-Service Poster
BIOPATCH Resource Guide
Testimonials
CDC Guidelines
References
*Based on 2017 market share data.
1. Ethicon Global Business Insights September 2017 Market Share Report.
2. HAIs at a Glance, CDC, http://www.cdc.gov/hai/surveillance/, 9 Jan. 2018. Accessed 11 May, 2018.
3. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp. Epidemiol 1999;20:396-401.
4. Maki DG, Chiacchierini RP, Hua S, Genthner D. An evaluation of BIOPATCH® Antimicrobial Dressing compared to routine standard of care in the prevention of catheter-related bloodstream infection. 2000.
5. Timsit J. et al. Chlorhexidine-Impregnated Sponges and Less Frequent Dressing Changes for Prevention of Catheter-Related Infections in Critically Ill Adults. JAMA. 2009; 301:1231-1241.
6. Zingg W, Pittet D. Peripheral venous catheters: an under-evaluated problem. Int J Antimicrob Agents 2009; 34 Suppl4:S38-42.
7. Lim S, Adams E, Hyde R, Broder M, Chang E, Reddy SR, Tarbox M, Bentley T, Ovington L. Clinical and Economic Burden of Peripheral Intravenous Catheter-Associated Complications in a U.S. Hospital Discharge Database. Poster presented at: 31st Annual Scientific Meeting of the Association for Vascular Access; 2017 Sep 16-19; Phoenix, AZ.
8. Shapiro JM, Bond EL, Garman JK. Use of a chlorhexidine dressing to reduce microbial colonization of epidural catheters. Anesthesiology. 1990;73:625-631
9. Hendley JO, Ashe KM. Effect of topical antimicrobial treatment on aerobic bacteria in the stratum corneum of human skin. Antimicrobial Agents and Chemotherapy. April 1991;35(4):627-631
10. Kovacs, CS, Fatica, C. Hospital-acquired Staphylococcus aureus primary bloodstream infection: A comparison of events that do and do not meet the central line-associated bloodstream infection definition. American Journal of Infection Control. 2016. http://www.ajicjournal.org/article/S0196-6553(16)30184-5/fulltext. Published online 5-5-16.
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.
© Ethicon US, LLC. 2019. 085133-171129
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.
This site is published by Ethicon US, LLC, which is solely responsible for its contents, and is intended for U.S. audiences only.
This site is intended for Healthcare Professionals. If you are a patient, it is important that you discuss information about the benefits and risks of products with your doctor.
Last updated February 20, 2019. The third-party trademarks used herein are trademarks of their respective owners. Data and usage fees may apply. See your carrier for more information.